CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer.

ABSTRACT: Cell cycle-dependent protein kinase 12 (CDK12) plays a key role in a variety of carcinogenesis processes and represents a promising therapeutic target for cancer treatment. However, to date, there have been no systematic studies addressing its diagnostic, prognostic and immunological value across cancers. Here, we found that CDK12 was significantly upregulated in various types of cancers, and it expression increased with progression in ten cancer types, including breast cancer, cholangiocarcinoma and colon adenocarcinoma. Moreover, the ROC curves indicated that CDK12 showed diagnostic value in eight cancer types. High CDK12 expression was associated with poor prognosis in eight types of cancer, including low-grade glioma, mesothelioma, melanoma and pancreatic cancer. Furthermore, we conduc

SUBMITTER: Lu KQ 

PROVIDER: S-EPMC10951204 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature